Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sounds attractive! Let us know how you make out with that look... it may be awhile ;)
I’m guessing that was Dawgbert from old yahoo posts. Very intelligent Inmed follower. Thanks for the repost Flair09 :)
I’m pretty sure it’s a 2 year grace period for making revenue.
I planned on participating with the webcast, but forgot to book myself off on my booking system... so now have to work during the phone in time :(
If anyone has the time... the one question I’m really curious to have answered : “Eric Adams said in an interview December 2016 that he was hoping to uplist to the NASDAQ within 2 years... are they still on that timeline?”
I totally goofed with my schedule! But looking forward to hearing anything our intelligent investors have to ask of the company!
Sorry greendragon420, I was running late this am and didn’t take the time to read your whole post. Keep us posted with WHO and/or Farm Bill! Cheers
The idea doesn’t suck all that much. I could see Aurora working as a distributor of product quite easily. Keeps Inmed’s hands clean of being a “pot stock”, so focus is on drug development, yet get to benefit from the huge cash Biosynthesis has the potential to make.
Same day, not exactly same time Aurora is 10:30am eastern, Inmed 10:00am pacific. I think just a coincidence.
I’m looking forward to the next webcast. I just listened to the last one, but this time I’m calling in with a question!
Conference Call & Webcast:
Monday, November 12, 2018 at 10:00 AM Pacific Time, 1:00 PM Eastern Time
Toronto:
+1-416-764-8688
Vancouver:
+1-778-383 7413
North America (Toll Free):
+1-888-390 0546
Conference ID:
01602924
Webcast:
https://event.on24.com/wcc/r/1869369/F1C676960976FEF685DFF9F12469BA4E
Wouldn’t that be lovely :)
New job posting for Scientist... looks like things are really ramping up.
https://www.inmedpharma.com/wp-content/uploads/2018/11/ScientistPreclinicalPharmacology.pdf
Plans and oversees the execution of research activities related to cannabinoid drug development in the fields of glaucoma and pain
• Designs and develops efficacy and pharmacology studies including biological assays and in-vivo models
• Assists in technology transfer of methods to qualified Contract Research Organizations (CROs)
• Maintains broad and current knowledge of state-of-the art principles and theories in the field of research
• Liaises with other internal scientists, and external collaborators and contractors
• Drafts reports, including protocols, technical reports, and related work instructions (WI)
and implements WI when needed to ensure accuracy and reproducibility in order to
Things are getting Real... very real! This company is far undervalued as we all know. I think Inmed is finally poised to be the most advanced contender in the Biosynthesis space.
Thanks Sam!
Dr. Vikramaditya G. Yadav, PhD
https://www.b-tv.com/inmed-pharmaceuticals-corporate-vikram/
Got it! Angel Investor my ash! Go ahead and delete
Les ;)
The “angel investor” Director Paul Chow has exercised 840 000 more .10 warrants from his seemingly unlimited supply. I spent the last couple hours stupidly going through each years financials to find these transactions to get an idea of how much more is coming. I found nothing back to 2015 year end. Most warrants typically expire 12-24 months after issue and most the time with an acceleration clause.
Very slick videos. Nice to see company working on exposure again.... hopefully they have something to pump this time.
Great post!
Thank you. Sounds like interesting weeks ahead. I must admit I’ve been very tardy in following my friends South of the border these days.
Another nice link today! When is this farm bill set to be voted on?
Good find! Josh Blacher did a really good job. The insight on the challenges with getting EB ready for trials was a great eye opener.
No worries... let the “powers at be “ do the delete. Sorry to call you out ;)
I’ve been invested with stock since the beginning. I thought of dumping it a few years ago, but decided to do a little more DD before. What I found out made me believe in it more and tripled down on my investment. This is a serious company now... and serious money will follow for those with the patience.
Ummm...ok greendragon420. What does this have to do with the conversations at hand?
From what I understand, BNN doesn’t do any live broadcasting over the weekend. Usually only repeats and infomercials on weekends. Let me know if you find a link!
Interesting thoughts. How do you think Eight Capital will benefit if this be the case? I’m sure they’re about the only ones that Eric Adams has any concerns with accountability right now.
The wait on the future announcements with this company is very frustrating, especially after Eric Adams all but declared the name of the future CMO. I know this step is important in bringing forward the drug platform, but feel the wait has been too long for the clinical trials for EB.
This keeps me going... from Inmed website.
Successes and Future Applications
We have successfully constructed the terpenoid biosynthetic pathway and the gateway pathway for synthesis of CBGA and the downstream pathways for synthesis of THCA and CBDA. Our proprietary pathway is significantly more productive than previously patented terpenoid pathways, and we have confirmed the biosynthesis of the cannabinoids using validated HPLC methodologies and 1H-NMR instrumentation.
We have constructed a series of E. coli strains that express variations and/or subsets of the entire biosynthetic pathway and have tested production in lab-scale fermentation tanks. Next steps in the biosynthesis program are to:
continue efforts to further diversify the number of cannabinoids produced using InMed’s system;
scale-up the biosynthesis process to larger vessels, where protocols will be developed to optimize manufacturing parameters; and
identify external vendors to assist in the commercial scale-up of the process.
Options for InMed’s GLP and GMP product manufacturing include either (1) building a dedicated biosynthesis facility or (2) transferring our process/know-how to a contract manufacturing organization with existing infrastructure to produce for us the preclinical, clinical and commercial scale supply of our product candidates.
In addition to providing a source of raw materials (active pharmaceutical ingredients, or “API”) for InMed’s therapeutic products, our biosynthesis program may play a significant role as a source of raw materials to other pharmaceutical companies, as well as a number to a number of other industries outside of the pharmaceutical segment.
The role of THC and CBD continues to expand at an exceptional rate in the recreational, nutraceutical and ‘medical marijuana’ spaces, where biosynthesis may prove to be an economical alternative to plant-sourced products. According to an October 2016 report issued by the Hemp Business Journal, the total consumer market for CBD alone is expected to surpass $2.1 billion by 2020, up from only $90 million in 2015. Estimates for the medical use of marijuana (delivering THC and CBD from the plant via smoking) have been estimated to be $12 billion in 2016 by Visiongain Ltd. and is expected to surpass $55 billion by 2025, according to a 2017 report by Grandview Research, Inc.
Offers are the same thing as “asks” in level 2 of your trading platform.
Let’s hope! Sure was nice seeing most the offers pulled today making some nice room for an easy run on some good news.
Wow! Put your seat belts on for tomorrow, could be another bumpy ride. We’re down around 30% in the last week. I don’t remember ever dropping this fast before :(
A breast cancer drug has been in the pipeline in the past... so won’t be surprised to see a reappearance. THC biosythesized could certainly send a man to the moon! I think Mengel’s predictions were extremely exaggerated and a little off a realistic timeline, but all us invested here have great expectations.
Whatever happened to Jimmy whats his name? We’re past the 3 month prediction... wonder how much money he had to pay back?
ANY IDEA WHICH COMPANY $.75/SHARE THAT HAS THE ANTI-CANCER PATENT BEING PITCHED BY THE OXFORD GROUP? CLAIMS FDA ANNOUNCEMENT IMMINENT WITHIN THE NEXT 90 DAYS AND THE STOCK EXPECTED TO EXPLODE BY 6263%
By psaw62, July 9, 2018
“A friend bought a subscription to Jimmie Mengel’s publication regarding this issue. The company was NOT revealed in the subscription, (pretty lame to tease a stock and then not reveal it to subscribers). My friend called the Oxford Club to cancel his subscription because the teaser stock had not been revealed. They gave him the name of the stock to keep him from canceling. The Oxford Club Staff advised that the stock is, in fact, InMed Therapeutics. IMLFF.”
Awww gee... thanks :)
Not even entertaining gents!
We’re certainly not performing like a stock on the verge of Greatness :(
That should be correct. Eight Capital infused a surprise infusion on top of the already oversubscribed financing. They must have something going on that’s good... something that’s a secret to long term holders ;)
Well that would suck immensely! Especially since GW will be the first customer at the door for this pharmaceutical grade CBD.
Ben Patterson who is working as a consultant for Inmed is from Eli Lilly & Martin Bott one of Inmed’s Directors is also from Eli Lilly. The comparisons between Inmed’s Biosynthesis process and Insulin Biosynthesis by Eli Lilly has been used strongly as comparables in publications for at least the last 2 years. So it’s safe to assume Eli Lilly is well aware of who and what Inmed Pharmaceuticals are.
In other words... it’s a logical guess/hope! I think we all realize the CMO can be anybody, but Eli Lilly’s name would give us some amazing exposure :)
I thought Adams referring to this company as a “secret” in his presentation was rather cheeky of him. He knows all us longs were listening in and this was going to take our hopes to the stratosphere! Why mention anything at all if you’re not willing to make it public knowledge... like I said CHEEKY!
It’s pretty painful waiting on the CMO announcement when Inmed has all but announced the name of the company!
Please Eric Ashley Adams tell us your secret!
Thank you! Certainly keeps hope up :)